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AbstrACt
background Rapidly undertaken age-stratified serology 
studies can produce valuable data about a new emerging 
infection including background population immunity and 
seroincidence during an influenza pandemic. Traditionally 
seroepidemiology studies have used surplus laboratory 
sera with little or no clinical information or have been 
expensive detailed population based studies. We propose 
collecting population based sera from the Royal College 
of General Practitioners (RCGP) Research and Surveillance 
Centre (RSC), a sentinel network with extensive clinical 
data.
Aim To pilot a mechanism to undertake population based 
surveys that collect serological specimens and associated 
patient data to measure seropositivity and seroincidence 
due to seasonal influenza, and create a population based 
serology bank.
Methods and analysis Setting and Participants: 
We will recruit 6 RCGP RSC practices already taking 
nasopharyngeal virology swabs. Patients who attend 
a scheduled blood test will be consented to donate 
additional blood samples. Approximately 100–150 blood 
samples will be collected from each of the following age 
bands – 18– 29, 30– 39, 40– 49, 50– 59, 60– 69 and 70+ 
years.
Methods We will send the samples to the Public Health 
England (PHE) Seroepidemiology Unit for processing 
and storage. These samples will be tested for influenza 
antibodies, using haemagglutination inhibition assays. 
Serology results will be pseudonymised, sent to the RCGP 
RSC and combined using existing processes at the RCGP 
RSC secure hub. The influenza seroprevalence results from 
the RCGP cohort will be compared against those from the 
annual PHE influenza residual serosurvey.
Ethics and dissemination Ethical approval was granted 
by the Proportionate Review Sub- Committee of the 
London – Camden & Kings Cross on 6 February 2018. This 
study received approval from Health Research Authority on 
7 February 2018. On completion the results will be made 
available via peer-reviewed journals.
IntroduCtIon  
rationale for the pilot study and background
There have been calls for a World Serology 
Bank as serology could tell us much about the 
susceptibility of the population to infectious 
disease.1 This pilot study explores the poten-
tial to establish a serology bank, based on a 
sentinel network, and focused on influenza.
Serological data potentially allow the assess-
ment of the severity of a new influenza strain 
by providing the capability to detect asymp-
tomatic and mild infections and thus deter-
mine the symptomatic proportion.2 The 
number of infections can be determined if the 
age-specific prevalence of immunity prior to 
and then during and after the pandemic are 
known. Thus, the number of people infected 
(and therefore no longer susceptible) can be 
calculated. If these data are available early 
(particularly the background population 
immunity and the symptomatic proportion), 
they can be used to adjust planning assump-
tions and to help predict the impact of the 
pandemic on healthcare services and optimal 
intervention strategies.
Serum archives would help assess the 
severity of a novel influenza virus and allow 
modification of local, national and interna-
tional pandemic plans.3 This requirement was 
a lesson from the 2009 A(H1N1) pandemic 
strengths and limitations of this study
 ► The RCGP RSC is one of the oldest sentinel net-
works in Europe, it has completed its 51st season 
of surveillance.
 ► Practices in RCGP take microbiological samples, 
including influenza virology specimens which are 
linked at individual level.
 ► We have the potential through this network to link 
vaccine exposure and serology.
 ► This is a pilot study to demonstrate we can collect 
samples across predefined adult age-groups – we 
will not collect samples from children, who may be 
exposed to live attenuated intranasal vaccine (LAIV) 
in recent years.
 ► Pharmacist and other non-GP vaccination can lead 
to missing information on the computerised medical 
record system at General Practice.
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and its importance is recognised by the WHO, the Euro-
pean Centre for Disease Control (ECDC), the UK Depart-
ment of Health, and the Joint Committee on Vaccination 
and Immunisation.
Despite its apparent merit, the use of serology for 
seasonal influenza surveillance has several limitations. 
Seasonal influenza infections occur regularly and individ-
uals are reinfected throughout life with related strains. 
The prior (lifetime) exposure of individuals to circulating 
influenza viruses in previous years and a high degree of 
cross-reactivity between antibodies to different seasonal 
influenza virus strains can lead to results which are diffi-
cult to interpret. Distinguishing between recent infection 
and recent vaccination also presents further difficulties. 
Consequently, seroepidemiological studies have not often 
been used for the investigation of seasonal influenza at a 
population level.
The UK undertook a series of influenza serosurveys 
during the 2009 pandemic based on residual blood 
samples from the Public Health England (PHE) National 
Seroepidemiology Programme.4 These are samples 
submitted to PHE and National Health Service (NHS) 
laboratories for routine diagnostic purposes. Although 
this work delivered critical information on background 
population seroprevalence and seroincidence, several 
issues were raised in postpandemic reviews. These reviews 
highlighted that, although this information was gathered 
and published earlier than almost any other country, even 
earlier availability of this intelligence would have been 
critical to inform important national policy decisions. 
The following key recommendations have been made in 
relation to influenza seroepidemiology.
 ► The Science and Technology Committee (third 
report 2010–2012) stated that seroepidemiological 
data need to be available earlier in the time course of 
a future pandemic to help with risk assessment (ie, the 
likely spread of the disease across the population).5
 ► The Chief Medical Officer-Statistics Legacy Group 
determined that serosurveillance is critical to deter-
mine population immunity and community infec-
tion rates. These data cannot be obtained from other 
sources and are vital to making modelling predictions 
of the pandemic.6
 ► The 2011 UK Influenza Pandemic Preparedness 
Strategy includes seroepidemiology as a key surveil-
lance initiative that will be required at the start of any 
pandemic, and states that work should be underway 
to enhance capability to respond, based on the H1N1 
(2009) influenza pandemic.7
 ► The Scientific Pandemic Influenza Advisory 
Committee (SPI), Subgroup on Modelling (SPI-M) 
group recommended that the PHE strengthen popu-
lation based influenza seroepidemiology, including 
collection of key epidemiological information on 
vaccination status and underlying risk status.8
 ► Finally ECDC has highlighted the importance of influ-
enza seroepidemiology, as has WHO as part of the 
Fineberg report into the pandemic response and the 
lack of preparedness including the need for a proper 
assessment of severity at national and subnational 
levels early in a pandemic.9
The Royal College of General Practitioners (RCGP) 
Research and Surveillance Centre (RSC) and PHE, and 
its predecessor organisations have an over 50-year history 
of collaboration in influenza and respiratory disease 
surveillance and vaccine effectiveness studies.10 This study 
builds on this long-term collaboration.
The RCGP RSC provides a suitable venue for collecting 
influenza serology data. This sentinel network is one of 
the longest established and has a nationally representa-
tive network of practices.11 The network has a long history 
of feedback about data quality, particularly in the areas 
of influenza-like illness (ILI) and other respiratory infec-
tions.12 The RCGP RSC also collects data about vaccine 
exposure. Combining information about ILI, virology 
results and vaccine exposure enables the estimation of 
influenza vaccine effectiveness.13 Its dashboard capability 
provides a method for near real time feedback to prac-
tices about sample collection.14
This pilot study tests whether collecting serology data 
from a sentinel network and linking it to clinical record 
data at the individual level would provide a low cost way 
of creating a high quality seroepidemiological resource.15
Aim
To pilot a mechanism to undertake population based 
surveys that collect serological specimens that will be 
linked with key epidemiological information at strategic 
time points after each influenza season as a resource to 
be deployed in a future pandemic, for seasonal influ-
enza and potentially other infections of public health 
importance.
objectives
 ► Establish a system that allows volunteer patients 
from practices to provide a serology sample during a 
routine blood test. The result of that sample will be 
linked to that patient’s pseudonymised record which 
will provide high quality data about vaccine exposure, 
and any medically reported ILI or other condition of 
scientific interest, included within an approved scien-
tific protocol, or meeting public health needs in a 
pandemic.
 ► Measure the feasibility of collecting 100–150 samples 
from each of the following age-bands – 18–29, 30–39, 
40–49, 50–59, 60–69 and 70+ years.
 ► Pilot laboratory programme for the processing and 
storage of these specimens.
 ► Pilot linkage of these biological specimens to the PHE 
Respiratory Virus Unit (RVU) analysis programme for 
the detection of influenza antibodies.
 ► Link the results to epidemiological data in particular 
vaccination history, age and underlying clinical risk 
factor status and any swab results. The serology results 
can be linked to vaccine brand.
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 ► Estimate the costs of providing a national seroepide-




Study setting and population
The project will consist of four interlinked 
work packages:




4. Statistical and modelling analysis.
Population sampling and collection of biological specimens
The RCGP RSC practices will collect the biological specimens.
The RCGP RSC will be used to collect the biological speci-
mens. Practices who participated in the virology swabbing 
scheme will be invited.
The project proposes to pilot a population based sero-
prevalence survey, involving 100–150 individuals across 
the following age range: 18–29, 30–39, 40–49, 50–59, 
60–69 and 70+ years, following the 2017/2018 influenza 
season. Patients, who attend their pilot sentinel network 
practice for routine blood test during the study period, 
will be asked to also provide an additional blood sample 
for serology. This will provide information on seroprev-
alence to set in context other measures of impact of an 
influenza season/epidemic in a population, and provide 
the most accurate measures of population exposure. This 
new approach to serology banking represents a compro-
mise between using residual serum samples from labora-
tories where less is known about the patient’s medical and 
immunisation history and formal surveys that can collect 
such data, but can have non-response bias.
Analysis will be carried out using the blood collected 
in RCGP RSC practices and sent to the Seroepidemi-
ology Unit (SEU) archive. The SEU archive is a collec-
tion of anonymised residual serum samples from routine 
microbiological testing, submitted voluntarily each year 
from laboratories throughout England. SEU archive sera 
are stored at the PHE North West regional laboratory 
in Manchester and are anonymised and permanently 
unlinked from any patient identifying information, with 
only age, gender, date of collection (if available) and 
contributing laboratory retained.
Serology samples will be analysed at the RVU at the PHE 
Colindale using HAI with representative vaccine strains. 
Each sample will be tested once and not in duplicate, 
the result will have strong identifiers pseudonymised (in 
accordance with current best practice) and be returned 
to the RCGP RSC hub’s encrypted server, decrypted and 
linked to individual patients pseudonymised data.
The RCGP RSC will recruit six practices (depending on 
practice list size) to ascertain the feasibility and establish 
the approach. We will aim to collect an evenly distrib-
uted set of sera across all age bands that are set out in 
table 1. Older people have more chronic disease and 
hence have higher number of blood tests performed than 
younger people; so the target number of samples would 
be achieved sooner. There will be no attempt to select 
patients for serology on the basis of whether they have 
had an influenza immunisation, or not or had a virology 
specimen taken for influenza. The number of samples is 
based on a combined list size of 50 000 across the partic-
ipating practices.
The proposed method would involve feeding back to 
practices as each age band reaches the target number of 
samples (minimum 100, maximum 150 per age band). 
University of Surrey has developed methods for RCGP 
RSC to give practice specific feedback about vaccine 
exposure and data quality – these methods could be used 




All patients of age 18 and over who visit their practice 
for a routine blood test and provide another sample for 
serology are eligible for inclusion in the analysis. The 
Table 1 Blood test plan for the pilot study
Age band
All practices (5–6 practices) during the study period
100 sample threshold crossed after the 
following number of weeks
150 sample threshold crossed after the 







This table represents the week in which sample collection would be complete, if all  patients  consented. The pilot study will take place as 
soon as ethical approval is achieved and would involve the collection of a total of up to 150 samples from approximately six practices over 
the study period.
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main inclusion criterion for practices is that practices are 
within our influenza swabbing practices’ list with quota 
sampling according to the table above.
 
Exclusion criteria
Patients who have explicitly opted out of data sharing 
will be excluded from the analysis. We will identify these 
patients using the opt-out codes within General Practice 
(GP) information systems where the patients have made 
an explicit choice to opt out; patients will be informed 
of their option to opt-out via posters in the practices and 
information sheets.
Laboratory analysis
Samples will be submitted to the PHE Manchester labora-
tory in practice batches of clotted vacutainer bottles, and 
will be accompanied by the standard request form. This 
form will be generated by existing ICE pathology request 
software used by the GP practices.
General Practices use a pathology request software, 
such as the ICE system to send biological specimens to 
their local laboratory for testing. When a patient requires 
a blood test, the GP can print a test request form via their 
ICE system. To send samples to PHE’s SEU/VEU:
 ► The practice will need to print out an additional test 
request form for routine blood sampling.
 ► The University of Surrey will provide the practices 
with detailed guidance on sample collection and 
postage to PHE’s SEU/VEU.
On receiving consent, practices will be able to send 
specimens to PHE’s SEU/VEU lab via pre-paid enve-
lopes. A Material Transfer Agreement (MTA) will be 
put in place for the transport of blood samples from 
GP practices to Manchester SEU/VEU.
We suggest a single Read code16 is allocated to mark 
that the serology specimen has been consented to and 
sent. This will facilitate one-to-one matching of specimens 
with the consenting patient/subjects clinical history.
Whole blood samples will be received, processed to 
obtain sera, catalogued and stored in −80° C archive 
freezers within the Serum Archives section of the Vaccine 
Evaluation Unit (VEU) at Manchester according to 
existing SOPs, modified where necessary. It is envisioned 
that sera collected will be permanently transferred to the 
SEU archive once this study is complete.
Sera will be processed to undergo analysis at the RVU 
of the National Infection Service of PHE (London, UK) 
using haemagglutination inhibition (HAI) assays and 
other measures of functional antibody status according 
to established protocols to detect antibody levels against 
relevant circulating and/or vaccine influenza strains.17 
Antigens will be grown in-house in egg and cell-culture 
and Influenza B antigens will be diethyl ether extracted 
as previously described.18 Briefly, for the HAI assay, sera 
will be treated to remove non-specific inhibitors using 
receptor destroying enzyme (RDEII) and then twofold 
serially diluted starting at a 1:10 dilution, followed by 
mixing with an equal volume (25 µl) of PBS containing 
4 HA units of each of the strains. Turkey red blood cells 
(RBC) will be used for the influenza A(H1N1)pdm09 
and influenza B components, and Guinea pig RBC for 
H3N2. HAI titres will be expressed as the reciprocal of 
the last serum dilution that results in complete inhibition 
of agglutination. Where sample volumes after completion 
of the HAI permit, additional analysis using influenza 
neutralisation and/or Neuraminidase Antibody Inhi-
bition assays in the format of the Enzyme-linked Lectin 
Assay16 may be considered to investigate the functionality 
of the antibody further.
Following analysis, the results will be reported in form 
of an Excel table (containing titres against each antigen/
influenza virus for every sample) to the data manager of 
the project. The data (with pseudonymised strong iden-
tifiers) will be linked to RCGP RSC data to allow analysis 
of relevant data including vaccine exposure and previous 
influenza.
Using the UK laboratory bounded code list
UK laboratories are currently obligated to use the 
Pathology Bounded Code List (PBCL), a subset of 
NHS Digital Read codes, when electronically reporting 
pathology results to GPs, but are freely allowed to choose 
which PBCL codes are used for each test. A PBCL code 
assigned to the test (table 2) will allow 1 week in areas 
for the RCGP RSC team to follow the collection of the 
samples by age band.
Data extraction and data management
Data collection from volunteer RCGP RSC practice
Data will be extracted from RCGP RSC databases which 
store pseudonymised data received from participating 
RCGP practices.10 A UK general practice is a registration 
based system where all citizens can register with a single 
GP of their choice. Practices are computerised, and data 
entered into computerised medical record systems either 
as coded data, or free text.
Practices will code 43 L. (Sample serology) into patient 
record when a patient consents to providing a sample for 
Serology. We will extract the coded data, and our results 
will be based on this element of the record. We will 
extract all coded data, pseudonymising as close to sources 
as possible. Where patients have a range of codes inserted 
in their record suggesting they opt out of record sharing 
we will not analyse their data.
The RCGP RSC will only extract coded data, for 
example, where the GP or other health professional codes 
a disease or symptom into their computerised medical 
record system, and will process these data as required for 
Table 2 Read codes to flag that a specimen has been 
taken
V2_READ_CODE V2_TERM
4JDb. Influenza (A&B) serology
43 L. Sample serology
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this project.17 19 Coded routine data from UK primary 
care has been widely used in research.20
Data collection methods will follow best practice, including 
pseudonymisation
These data extractions will be conducted in accordance 
with best practice, using the Clinical Informatics and 
Health Outcomes Research Group’s standard operating 
procedures for data extraction, pseudonymisation, and 
transfer. The method and governance procedure has 
been developed by the University of Surrey, using an 
approved provider.
Pseudonymisation is the standard approach for 
protecting patient’s privacy. It is a process that involves 
the removal of all personal identifiers from data – such 
as name, date of birth, etc. However, there is a risk that 
if data are linked to other data a person might be identi-
fied.21 22 Therefore although all identifiers are removed 
we keep data encrypted during transfer and on a secure 
network that meets NHS Information Governance stan-
dards to minimise the risk of re-identification. A legally 
binding definition of pseudonymisation has been intro-
duced into European law on the recommendation of the 
European Data Protection Supervisor (EDPS).19
We ‘pseudonymise’ strong identifiers (in this study 
NHS number) so that we can link further data to the same 
individual’s record. For this study we need, for example, 
to be able to link whether there have been any immune 
changes to the individual that had been vaccinated (and 
with the specific brand and batch number). Pseudony-
misation allows us to do this without knowing any of the 
strong personal identifiers of that individual.
All data processing and analysis in the present 
proposed study will be conducted within the secure IT 
environment of the Clinical Informatics and Health 
Outcomes Research Group, at the University of Surrey. 
The information security policies and procedures of the 
Research Group have been approved by the NHS Digital 
as meeting the Information Governance Toolkit (IGT) 
standards.23
The following routinely collected patient data will be 
collected for the study:
 ► Demographic information: age, gender, ethnicity, 
registered date.
 ► Lower Super Output Area (LSOA): full postcodes will 
be automatically and immediately transformed into 
Lower Super Output Area (LSOA) which can be used 
for calculating deprivation scores, using the Index 
of Multiple Deprivation (IMD), within GP computer 
systems on extraction. This would provide informa-
tion about any inequities in access according to level 
of social deprivation using geographical information 
system (GIS) methods.
 ► Influenza vaccination – including date of vaccination 
and brand/lot
 ► Primary care consultations following vaccination, any 
other markers of healthcare utilisation, and referral 
to further care.
 ► Reactogenicity outcomes of seasonal influenza vacci-
nation as listed in the research literature and any 
contemporary EU guidance.
 ► Life-style/risk factors – for example, Body Mass Index 
(BMI), smoking status.
 ► Records of other diseases and long term conditions 
– for example, chronic respiratory disease, chronic 
heart disease, chronic kidney disease, chronic liver 
disease, chronic neurological disease, diabetes, immu-
nosuppression, pneumonia, etc.
 ► Pregnancy.
 ► PHE results of influenza HAI testing will be linked to 
this data-set at the University of Surrey according to 
established information governance (IG) procedures
Practices will receive weekly feedback via our dashboard 
system about progress to target within each age band 
(table 1).15
Data tables for analysis
RCGP RSC will prepare tables for analysis as set out in 
the section below on statistical modelling and analysis. 
A schedule for reports would be created, as is currently 
carried out for reporting influenza vaccine effectiveness 
studies, and blank tables prepared in advance as outlined 
in this protocol.
Statistical and modelling analysis
PHE will lead on this analysis and follow the outline plan 
set out below.
The proof-of-concept study will consist of a total of up 
to 100–150 participants per age band from whom blood 
samples have been taken during the survey period.
The evaluation will include the following elements:
 ► A comparison of representativeness of the recruited 
study population will be undertaken in relation to 
national surveys.
 ► A comparison of the influenza seroprevalence results 
from the RCGP cohort against those from the annual 
PHE influenza residual serosurvey
 ► Demographic, epidemiological and lab data will be 
checked for completeness, errors and inconsistencies
 ► Samples with titres>40 by HAI will be considered sero-
positive to report prevalence of influenza antibody 
detected by HAI.4 In addition, geometric mean titres 
and reverse cumulative distribution curves will be 
calculated for some preliminary, exploratory compar-
isons of groups such as those vaccinated versus unvac-
cinated – although conclusions will be limited by the 
samples available.
 ► Acceptability to participate among practices and 
patients ascertained through measures such as 
response rate.
 ►  Feasibility of extending the pilot approach to a wider 
number of practices.
University of Surrey will report the extent to which 
we have samples from common households – this might 
provide information about shared infections/levels of 
immunity within households.
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We will produce a weekly report on progress to target 
by age band and provide feedback to practices about the 
utility of the data provided. This will be a simple table – 
based on table 1, explaining the anticipated number of 
weeks to complete the sampling by age band.
Patient and public involvement
No patients or public were involved in the development 
of the research question or design of this study.
Project management
The pilot project will be a collaborative project lead by 
Professor Simon de Lusignan at University of Surrey, with 
RCGP and PHE as collaborators. The RCGP-PHE scien-
tific committee will oversee the project in collaboration 
with the principal investigator.
This research and information governance framework 
for RCGP RSC sits within the University of Surrey’s formal 
frameworks for information and research governance. In 
addition, all externally funded projects and collaborative 
projects with external partners are supported and guided 
by the University’s Research and Enterprise Support 
(RES) service. RES ensures that university-supported proj-
ects are financially viable, and that legal issues of knowl-
edge transfer and intellectual properties are addressed. 
The project team is supported by IT services dedicated to 
the Faculty and to the Department of Clinical and Exper-
imental Medicine. Our secure analysis servers are opti-
mised for routine healthcare data processing, to provide 
faster deliveries for our projects.
EthICs And dIssEMInAtIon
Ethical Approval
 PHE has ethical approval (05/Q0505/45) for the collec-
tion and use of unlinked and anonymised residual serum 
samples in cross-sectional antibody prevalence studies 
for the surveillance of population immunity to vaccine 
preventable diseases of public health importance and the 
collection has been extensively used for this purpose. 
We will seek to collect serum samples from a cohort 
of patients that are registered with one of the RCGP 
RSC practices. Potential participants will be attending a 
pre-scheduled blood appointment, where the healthcare 
professional treating them will inform them about the 
study and seek their consent about whether they would 
be interested in donating an additional blood sample as 
part of the study.
Ethical approval was granted by the Proportionate 
Review Sub- Committee of the London – Camden & Kings 
Cross on 6 February 2018. This study received approval 
from Health Research Authority on 7 February 2018.
Blood serum is acellular and not considered a material 
subject to the Human Tissue Act 2004.24 However, prac-
tices will all need to put in place a MTA with PHE prior to 
starting their surveillance.25
Information governance
The Clinical Informatics and Health Outcomes Research 
Group at the University of Surrey has worked with 
routinely collected healthcare data in a number of 
research and evaluation projects for over 20 years.26 The 
Research Group works within the research and Informa-
tion Governance frameworks for health and social care in 
the United Kingdom, and is compliant with the Univer-
sity’s best practice standards. The University of Surrey is 
registered with the Information Commissioner’s Office 
Data Protection Register, and is compliant with the Data 
Protection Act, and other legislations.
In addition, the Research Group reviewed its depart-
mental information governance policies and procedures, 
against the requirements of the NHS IGT for Hosted 
Secondary Use Team/Project, Version 14.1.20
dissemination and public register disclosure
The outputs from the research will be disseminated 
primarily through peer review papers in high impact 
journals within the domains of primary care, surveillance, 
vaccines and infectious diseases.27,28 We will present find-
ings at relevant seminars and conferences. The Univer-
sity of Surrey, in accordance with PHE policy, will post 
a summary of the study protocol and results within 12 
months of study completion.
dIsCussIon
strengths
The strengths of this application are that it uses an estab-
lished sentinel network and builds on PHE expertise in 
serological analysis to establish a serology bank.
The RCGP RSC is a sentinel network that collects and 
monitors data from primary care, particularly influenza 
and other respiratory illnesses, with some practices in 
the network that have been providing data for decades.11 
These practices have data quality that is as good as it 
gets in primary care and the practices are used to taking 
specimens.
PHE has expertise in serology, but many of serosurveys 
used residual serum samples from diagnostic blood tests4 
and hence the clinical information available with these is 
very limited. Detailed serology surveys are also conducted, 
but these are extremely expensive.
In this pilot the serology sampling has been designed 
to provide almost real time results which can be linked 
to pseudonymised patient data extracted by RCGP RSC. 
Conducting the sampling alongside routine blood tests 
reduces overall time for practices and costs overall.
Collection from the same household may result in 
selection bias as it is likely that they will have had similar 
exposures; however, it is also a possible strength of the 
network in trying to understand more about transmission 
within households or communal establishments, such as 
old peoples’ homes.
We will create a database with individual level serology, 
virology specimens (if any) confirming influenza or other 
respiratory disease diagnoses, details of past medical 
history and vaccine exposure data.
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limitations
This pilot is limited by its design as a pilot within the avail-
able resource envelope and data quality. The limitations 
of this study are: its small size, limitation to adult speci-
mens only, no specific targeting of those who have had 
previous virology or at specific points within the annual 
cycle of vaccination or of influenza infection and data 
quality particularly of out-of-practice vaccine exposure.
We set an arbitrary collection strategy across adult 
age bands. However, this distribution is not representative 
of our practices populations’ age distribution. Any full-
scale study would set out to represent the age–sex profile 
of the population and its geographical distribution.
The study is not powered to detect differences between 
groups, instead to demonstrate our ability to collect 
samples across all age groups. The ability to collect across 
all age groups have been questioned – both by the orig-
inal authors of the call for a World Serology Bank,29 and 
set as a principal challenge by potential funders if the 
pilot is a success. Hence the focus of the pilot is on sample 
collection across age groups.
We have not included children or young people under 
18 years in this pilot. We feel this is appropriate for the 
first pilot of this type. In a substantive study, this group 
may be important because children are important vectors 
of disease30 and the UK is one of the few countries to 
systematically immunise the population using live atten-
uated intranasal vaccine (LAIV).31
This pilot is not targeting those who have had virology 
specimens, nor to be aligned with a particular point in 
the vaccination cycle. Generally vaccination takes place 
in the early autumn in the UK, with seasonal influenza 
starting to circulate around the year end. In a major study 
it may be possible to look at immunity in the population, 
exposed and unexposed to vaccine, and at residual immu-
nity to the circulating strain of influenza.
Patients vaccinated against influenza outside of 
General Practice may not have information coded into 
their computerised medical record system at General Prac-
tice.32 Vaccination data are sometimes missing, or some-
times incomplete as the standard reporting form from 
pharmacist to practice only indicate that the person has 
been vaccinated against influenza, not which brand of 
vaccine or batch.
ConClusIon
This pilot tests our ability to collect samples across all 
adult age bands within a sentinel network. If successful we 
will pursue resources to expand this into a larger study.
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